Core Points - Vanda Pharmaceuticals Inc. will participate in the Stifel 2025 Healthcare Conference in New York City on November 12, 2025, with a corporate presentation scheduled for 4:40 p.m. Eastern Time [1] - The corporate presentation can be accessed live on Vanda's corporate website, and investors are encouraged to register and prepare at least 15 minutes in advance [2] - Vanda is a leading global biopharmaceutical company focused on developing innovative therapies to meet high unmet medical needs [3] Financial Results - Vanda Pharmaceuticals announced it will release its financial and operational results for the third quarter ended September 30, 2025, on October 29, 2025 [5]

Core Insights - AnaptysBio, Inc. reported strong financial results for Q3 2025, with a net income of $15.1 million for the quarter, marking a significant improvement compared to a net loss of $32.9 million in Q3 2024 [14][23]. - The company announced its intent to separate its biopharma operations from its royalty assets by the end of 2026, aiming to unlock potential value for investors [5][16]. Financial Performance - Collaboration revenue for Q3 2025 was $76.3 million, up from $30.0 million in Q3 2024, driven primarily by Jemperli sales exceeding $750 million [17][23]. - Research and development expenses decreased to $31.4 million in Q3 2025 from $42.2 million in Q3 2024, while general and administrative expenses remained relatively stable [17][23]. - Cash and investments totaled $256.7 million as of September 30, 2025, down from $420.8 million at the end of 2024, primarily due to operating activities and share repurchases [17][20]. Business Updates - Jemperli sales grew to $785 million year-to-date in 2025, with a quarter-over-quarter growth of over 16% [5][6]. - Anaptys anticipates a one-time $75 million commercial sales milestone in Q4 2025 from GSK once Jemperli achieves $1 billion in worldwide net sales [5][6]. - The company is on track to report top-line Phase 2 data for rosnilimab in ulcerative colitis in November or December 2025 [5][13]. Strategic Initiatives - The planned separation will create two independent publicly traded companies, allowing investors to align their portfolios with distinct business objectives [6][16]. - The biopharma operations will focus on innovative immunology therapeutics, including rosnilimab, ANB033, and ANB101, while the royalty management company will handle royalties and milestone payments [6][16]. Clinical Development - Rosnilimab's Phase 2b data in rheumatoid arthritis was presented at ACR Convergence 2025, showing promising response rates [13]. - A Phase 1b trial for ANB033 in celiac disease has been initiated, with top-line data expected in Q4 2026 [5][13].

Financial Performance - Total revenues for the three months ended September 30, 2025, were $56,258,000, an increase of 18% compared to $47,651,000 for the same period in 2024[15] - Net product sales for the nine months ended September 30, 2025, reached $158,889,000, up from $145,587,000 in 2024, reflecting a growth of 9%[15] - The net loss for the three months ended September 30, 2025, was $22,586,000, compared to a net loss of $5,324,000 for the same period in 2024[15] - The company reported a comprehensive loss of $22,442,000 for the three months ended September 30, 2025, compared to a comprehensive loss of $4,292,000 in 2024[17] - For the nine months ended September 30, 2025, total revenue was $158,889,000, an increase of 9.5% from $145,587,000 in 2024[78] Expenses - Research and development expenses for the three months ended September 30, 2025, were $22,563,000, a 35% increase from $16,776,000 in 2024[15] - Selling, general and administrative expenses for the nine months ended September 30, 2025, totaled $174,973,000, compared to $107,132,000 in 2024, marking a significant increase of 63%[15] - Selling, general and administrative expenses rose significantly to $60,273,000 for the three months ended September 30, 2025, compared to $37,573,000 in 2024, marking a 60.5% increase[78] - Stock-based compensation expense for the nine months ended September 30, 2025, was $7.189 million, compared to $9.569 million for the same period in 2024, showing a decrease of approximately 25.5%[23] Cash and Assets - Cash and cash equivalents as of September 30, 2025, were $70,022,000, down from $102,316,000 as of December 31, 2024[14] - Total assets decreased to $601,140,000 as of September 30, 2025, from $656,204,000 as of December 31, 2024[14] - The total stockholders' equity decreased to $465.999 million as of September 30, 2025, down from $544.910 million at the end of 2024, reflecting a decline of approximately 14.4%[21] - Cash and cash equivalents decreased to $70.491 million at the end of September 2025, down from $102.785 million at the beginning of the period, representing a decrease of 31.4%[23] Inventory and Sales - Inventory as of September 30, 2025, totaled $10.039 million, an increase from $9.513 million as of December 31, 2024[45] - HETLIOZ net product sales for the nine months ended September 30, 2025, were $55.042 million, a decrease of 2.8% from $56.631 million in 2024[34] - The company recognized $5.8 million of net product sales during the nine months ended September 30, 2025, related to changes in estimates on variable consideration for performance obligations satisfied in previous periods[35] - Major customers accounted for 77% of total revenues for the nine months ended September 30, 2025, indicating a high concentration of revenue sources[36] Legal Matters - The company is involved in ongoing patent infringement lawsuits against Teva and Apotex regarding HETLIOZ, with a trial scheduled for August 3, 2026[79] - The company filed a lawsuit against the FDA challenging the approval of Teva's ANDA for its generic version of HETLIOZ, which is currently pending[80] - The company has filed multiple lawsuits against the FDA to compel the production of records under FOIA, with nine cases resolved in its favor[82] - The company is appealing a ruling against its request for Fast Track designation for tradipitant, with the case currently pending in the U.S. Supreme Court[82] Future Developments - The company is focused on obtaining FDA approvals for several products, including Bysanti and PONVORY, to expand its market presence[12] - Vanda is actively developing several new therapies, including a long-acting injectable formulation of Fanapt for schizophrenia and Tradipitant for various conditions, indicating ongoing innovation[29] - The Company has remaining milestone obligations of $10.0 million and $5.0 million for tradipitant's first approval in the U.S. and E.U., respectively[51] Shareholder Information - The weighted average shares outstanding for the three months ended September 30, 2025, were 59,091,478, compared to 58,261,961 for the same period in 2024[15] - As of September 30, 2025, there were 7,975,115 shares subject to outstanding options and RSUs under the equity incentive plans[61] - The Company granted 1,966,625 RSUs during the nine months ended September 30, 2025, with a weighted average grant date fair value of $4.46[68] Tax and Income - The Company recorded an income tax benefit of $21.4 million for the nine months ended September 30, 2025, compared to $2.4 million for the same period in 2024[71] - The company reported comprehensive income of $540 thousand for the nine months ended September 30, 2025, compared to a comprehensive loss of $30 thousand for the same period in 2024[23]

Company Performance - Vanda Pharmaceuticals reported a quarterly loss of $0.38 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.31, and compared to a loss of $0.09 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $56.26 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 6.24%, but showing an increase from $47.65 million in the same quarter last year [2] - Over the last four quarters, Vanda has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Outlook - Vanda shares have increased by approximately 16.5% since the beginning of the year, slightly underperforming the S&P 500's gain of 17.2% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.20 on revenues of $64 million, and for the current fiscal year, it is -$1.75 on revenues of $226.63 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Vanda belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable environment for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]

Financial Data and Key Metrics Changes - Total net product sales for Q3 2025 reached $56.3 million, an 18% increase year over year, driven by a 31% increase in Fanapt sales and a 35% growth in prescriptions [5][22] - For the first nine months of 2025, total revenues were $158.9 million, a 9% increase compared to $145.6 million for the same period in 2024 [17] - The net loss for the first nine months of 2025 was $79.3 million, compared to a net loss of $14 million for the same period in 2024 [19] Business Line Data and Key Metrics Changes - Fanapt net product sales for Q3 2025 were $31.2 million, a 31% increase compared to $23.9 million in Q3 2024 [22][23] - Helios net product sales were $18 million for Q3 2025, a 1% increase compared to $17.9 million in Q3 2024 [25] - PONVORY net product sales were $7 million for Q3 2025, a 20% increase compared to $5.9 million in Q3 2024 [27] Market Data and Key Metrics Changes - Fanapt total prescriptions increased by 35% compared to Q3 2024 and 11% compared to Q2 2025 [24] - Helios continues to retain the majority of market share despite generic competition for over two and a half years [18] - PONVORY has shown an increase in underlying patient demand for the second consecutive quarter [36] Company Strategy and Development Direction - The company is investing strategically in its commercial infrastructure to support long-term market leadership and future commercial launches [6][10] - The company aims to achieve total revenues from Fanapt, Helios, and PONVORY of between $210 million and $230 million for 2025 [37] - The company expects to have six products commercially available in 2026, including tradipitant and Visanti [36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the collaborative framework with the FDA and the potential for tradipitant approval by December 30, 2025 [44] - The company anticipates continued growth in Fanapt revenue, driven by the expanded sales force and increased market presence [37][61] - Management noted that Helios revenue can be variable from quarter to quarter, depending on customer purchasing patterns [60] Other Important Information - The company recorded a significant increase in operating expenses, primarily driven by higher SG&A and R&D expenses related to commercial launches [20][32] - Cash and cash equivalents as of September 30, 2025, were $293.8 million, a decrease of $80.9 million compared to December 31, 2024 [21] Q&A Session Summary Question: Comments on FDA interactions and potential approval timelines for tradipitant - Management is optimistic about the tradipitant review and expects a decision by December 30, 2025, with no efficacy issues raised so far [44][45] Question: Future growth expectations for PONVORY - Management indicated that underlying patient demand for PONVORY has increased, and they expect this trend to continue as the sales force is fully staffed [50][51] Question: Guidance change and its implications - The guidance reflects strong Fanapt revenue growth, but Helios revenue may vary based on customer purchasing patterns [60][61] Question: Engagement with the FDA regarding Visanti - Management reported positive interactions with the FDA regarding Visanti, with no issues raised on efficacy and safety [63] Question: Marketing strategy for upcoming product launches - The company is developing a consumer-centric marketing strategy for tradipitant and Helios, focusing on brand awareness and concierge services [69]

Sales Performance - Total net product sales reached $56.3 million in Q3 2025, an 18% increase from $47.7 million in Q3 2024[6] - Fanapt sales increased by 31% to $31.2 million in Q3 2025 compared to $23.9 million in Q3 2024[5] - HETLIOZ sales were $18.0 million in Q3 2025, a slight increase of 1% from $17.9 million in Q3 2024[6] - PONVORY sales grew by 20% to $7.0 million in Q3 2025 compared to $5.9 million in Q3 2024[6] - Total revenues for Q3 2025 reached $56.258 million, a 18% increase from $47.651 million in Q3 2024[21] - Net product sales for Fanapt® were $31.245 million, up 30% from $23.919 million in the same quarter last year[21] Financial Losses - Net loss for Q3 2025 was $22.6 million, compared to a net loss of $5.3 million in Q3 2024[11] - The net loss for Q3 2025 was $22.586 million, compared to a net loss of $5.324 million in Q3 2024[21] - The company reported a loss before income taxes of $28.390 million for Q3 2025, compared to a loss of $6.244 million in Q3 2024[21] Cash and Assets - Cash and cash equivalents totaled $293.8 million as of September 30, 2025, a decrease of $31.8 million from June 30, 2025[6] - Total current assets decreased to $367.496 million from $438.890 million as of December 31, 2024[23] - Cash and cash equivalents declined to $70.022 million from $102.316 million at the end of 2024[23] - Total liabilities increased to $135.141 million, up from $117.658 million at the end of 2024[23] - The accumulated deficit rose to $253.579 million from $174.292 million as of December 31, 2024[23] Research and Development - Research and development expenses increased to $22.563 million, a 35% rise compared to $16.776 million in Q3 2024[21] Future Guidance and Milestones - Vanda expects total revenues for 2025 to be revised to $210 to $230 million, down from the previous guidance of $210 to $250 million[13] - The PDUFA target action date for the Tradipitant NDA for motion sickness is December 30, 2025[5] - The PDUFA target action date for the Bysanti NDA for bipolar I disorder and schizophrenia is February 21, 2026[5] - A clinical study of Tradipitant in preventing vomiting induced by Wegovy is complete, with results expected in Q4 2025[10] Shares Outstanding - Weighted average shares outstanding remained stable at approximately 59.1 million for both basic and diluted calculations[21]

Core Insights - Vanda Pharmaceuticals reported strong commercial execution in Q3 2025, with total net product sales reaching $56.3 million, an 18% increase year-over-year, driven by a 31% increase in Fanapt sales and a 35% growth in prescriptions [2][7] - The company is advancing its pipeline with multiple near-term regulatory milestones, including the NDA for tradipitant and Bysanti, both under FDA review, and the anticipated submission of the imsidolimab BLA [2][6] Financial Highlights - In Q3 2025, Vanda reported a net loss of $22.6 million, compared to a net loss of $5.3 million in Q3 2024, with diluted net loss per share at $0.38 [4][7] - For the first nine months of 2025, the net loss was $79.3 million, compared to $14.0 million in the same period of 2024, with diluted net loss per share at $1.35 [5][7] Operational Highlights – Commercial - Fanapt net product sales increased by 31% to $31.2 million in Q3 2025 compared to Q3 2024, while HETLIOZ sales were stable at $18.0 million, a 1% increase [7][6] - The direct-to-consumer campaign launched in Q1 2025 has significantly improved brand awareness for Fanapt and PONVORY [7] Operational Highlights – Regulatory & Clinical Development - The NDA for tradipitant for motion sickness is under FDA review with a PDUFA target action date of December 30, 2025, and the Bysanti NDA for bipolar I disorder and schizophrenia has a PDUFA target action date of February 21, 2026 [6][7] - A clinical study of tradipitant in preventing vomiting induced by Wegovy is complete, with results expected in Q4 2025 [7]

Core Viewpoint - Vanda Pharmaceuticals Inc. is set to release its third quarter 2025 financial results on October 29, 2025, after market close, followed by a conference call to discuss the results and corporate activities [1][2]. Financial Results Announcement - The financial results for Q3 2025 will be announced on October 29, 2025, after the market closes [1]. - A conference call will be held at 4:30 PM ET on the same day to discuss the results [2]. Conference Call Details - Participants can join the conference call by dialing 1-888-596-4144 for domestic calls or 1-646-968-2525 for international calls, using passcode 8728050 [2]. - The call will be broadcast live and archived on Vanda's website, with a recommendation for investors to register at least 15 minutes early [3]. Replay Information - A replay of the conference call will be available starting at 8:30 PM ET on October 29, 2025, until November 5, 2025, at 11:59 PM ET [4]. - The replay call-in number is 1-800-770-2030 for domestic callers and 1-609-800-9909 for international callers, with the same passcode [4]. Company Overview - Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on developing and commercializing innovative therapies to meet high unmet medical needs [5].

Core Viewpoint - Vanda Pharmaceuticals has established a collaborative framework with the FDA to resolve disputes regarding its drugs HETLIOZ and tradipitant, which includes expedited reviews and temporary pauses in ongoing litigation [1][3]. Summary by Relevant Sections Agreement with FDA - Vanda Pharmaceuticals has agreed on a collaborative framework with the FDA to address disputes related to HETLIOZ (tasimelteon) and tradipitant [1]. - The FDA will conduct an expedited re-review of the partial clinical hold on tradipitant for motion sickness by November 26, 2025, and continue its review of the New Drug Application (NDA) with a target action date of December 30, 2025 [3]. Drug Applications and Reviews - The FDA will also expedite the re-review of Vanda's supplemental NDA for HETLIOZ for jet lag disorder by January 7, 2026, focusing on sleep-related aspects [3]. - Vanda and the FDA will seek a temporary pause in ongoing administrative proceedings related to tradipitant for gastroparesis until January 7, 2026 [3]. Legal Actions - Vanda will dismiss its lawsuits challenging the FDA's practices regarding drug application timelines and the partial clinical hold on tradipitant [3].

Core Viewpoint - AnaptysBio, Inc. plans to separate its business into two independent, publicly traded companies, "Royalty Management Co" and "Biopharma Co," to enhance value and align with different investment strategies [1][14]. Group 1: Business Separation - The separation aims to create two distinct entities, allowing investors to align their portfolios with the strategic opportunities of each company [1][14]. - Royalty Management Co will manage rights to royalties and milestone payments from collaborations, focusing on maximizing shareholder value [3][6]. - Biopharma Co will concentrate on developing innovative therapeutics for autoimmune and inflammatory diseases, including rosnilimab, ANB033, and ANB101 [10][13]. Group 2: Financial Collaborations and Royalties - Anaptys has financial collaborations with GSK and Vanda, which include substantial potential royalties and milestone payments [2][8]. - GSK's Jemperli has shown strong sales performance, with $262 million in Q2 2025 and projected peak sales exceeding $2.7 billion [4][5]. - The royalty structure from GSK includes tiered royalties based on net sales, with rates ranging from 8% to 25% depending on sales thresholds [5][6]. Group 3: Clinical Development Pipeline - Rosnilimab has completed a Phase 2b trial for rheumatoid arthritis and is in a Phase 2 trial for ulcerative colitis, with data expected in late 2025 [11][18]. - ANB033 is in a Phase 1b trial for celiac disease, while ANB101 is in a Phase 1a trial targeting autoimmune diseases [12][13]. - The outcomes of these clinical trials will influence the economic value allocation between the two new companies [11]. Group 4: Future Plans and Leadership - The separation is anticipated to be completed by the end of 2026, with Daniel Faga expected to lead Biopharma Co [14]. - Specific details regarding the transaction, board composition, and financial operations will be disclosed later [14][15].